Histiocytic sarcoma with secondary involvement of the skin and expression of CD1a: evidence of indeterminate cell differentiation?
BACKGROUND
Histiocytic sarcoma is an exceedingly rare malignant neoplasm composed of cells with a monocyte/macrophage phenotype. In the current nosology of histiocytic neoplasms, histiocytic sarcoma is separate from indeterminate cell histiocytosis, a generally benign disorder characterized by proliferation of a CD1a+ and S-100+ population of cells lacking Birbeck granules usually limited to the skin.


METHODS
We present a case of histiocytic sarcoma in a 64-year-old man presenting as a peritonsillar mass and secondarily involving the skin.


RESULTS
The malignant cells in the extracutaneous foci of disease expressed macrophage-associated antigens including S-100 but were CD1a-. The malignant cells in the skin coexpressed CD1a and S-100 but lacked ultrastructural features of Langerhans cells, findings indicative of indeterminate cells.


CONCLUSIONS
We discuss the clinical and histopathologic differential diagnosis in association with prior reported cases of histiocytic sarcoma, particularly in cases involving the skin and cases expressing the Langerhans cell-associated antigen CD1a.
Frater
John L
JL
Department of Pathology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.
Kling
Christopher W
CW
Obadiah
Joseph M
JM
Gardner
Laura J
LJ
Grosso
Leonard E
LE
Resh
Brooke
B
Hurley
M Yadira
MY
D018949:Antigens, CD1 / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D001761:Bleomycin / Q000008:administration & dosage; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006644:Histiocytes / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D012509:Sarcoma / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D012878:Skin Neoplasms / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D014067:Tonsillar Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D014750:Vincristine / Q000008:administration & dosage
D018949:Antigens, CD1; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C419393:CD1a antigen; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone